Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
NCT07213648
Anxiety Disorders, Basal Ganglia Diseases
Charlottesville, Virginia, United States
View Trial DetailsNCT Number: NCT05707663
The goal of this observational study is to learn about brain development in Juvenile-onset Huntington's Disease (JoHD). The main questions it aims to answer are:
* Is brain development different in JoHD than Adult-onset Huntington's Disease (AoHD)? * Can reliable biomarkers for JoHD be found in brain structure and function?
Participants will be asked to complete cognitive tests, behavioral assessments, physical and neurologic evaluation, and MRI. Data collected will be compared to populations who are at-risk for HD and who have been diagnosed with HD as adults.
This study is active but is not currently recruiting participants.
Notify Me4 year–30 year
All sexes
Observational
University of California Davis, Sacramento, California, United States
Huntington's disease (HD) is a genetic neurodegenerative disorder caused by an abnormal expansion of a trinucleotide CAG repeat region of the huntingtin gene (HTT). The majority of patients with HD do not present with symptoms until the age of 40-50 years old, on average, which is referred to as Adult-onset HD (AoHD). A much smaller percentage of patients with HD receive a motor diagnosis prior to the age of 21, which is referred to as Juvenile-onset HD (JoHD). Although patients with JoHD have the same core triad of cognitive, behavior, and motor symptoms, there are unique clinical characteristics that are distinct from AoHD. Specifically, patients with JoHD have less chorea compared to patients with AoHD, often presenting with rigidity and bradykinesia. However, due to the rarity, there is a lack of data regarding symptom characterization, neurobiology and progression of JoHD. Large-scale observational studies have been performed in AoHD, which have broadened our understanding of HD and opened the doors for the development and conduct of clinical trials. Patients with JoHD have been excluded from clinical trials, leaving patients and their families feeling hopeless and abandoned by the scientific community. Large-scale, longitudinal studies in patients with JoHD are critical to bettering our understanding of this devastating disease and providing hope to patients who have felt left behind as therapeutic strategies advance in AoHD.
In an effort to better understand the developmental aspects of this brain disease, the current study proposes to evaluate brain structure and function in children, adolescents, and young adults (ages 6-30) who have been diagnosed with JoHD. Brain structure will be evaluating using Magnetic Resonance Imaging (MRI) with quantitative measures of the entire brain, cerebral cortex, as well as white matter integrity via Diffusion Tensor Imaging. Brain function will be assessed by cognitive tests, behavioral assessment, and physical and neurologic evaluation. This study will test the hypothesis that comprehensive and longitudinal assessments of brain function and brain structure may produce reliable biomarkers of disease progression in JoHD.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 60-90 minutes out of 7-8 hour testing day
Magnetic Resonance Imaging (MRI) and Diffusion Tensor Imaging (DTI) data will be analyzed to assess brain structure based upon variables including global volume, total cerebral spinal fluid, subregion volumes, cortical surface anatomy including cortical depth, surface area and gyral shape, and symmetry between brain hemispheres.
Time frame: 5 hours out of 7-8 hour testing day
Participants undergo a cognitive battery which will quantify skills such as attention, learning, memory. In addition, behavioral measures will be administered in both self and proxy report formats.
Time frame: 1 hour out of 7-8 hour testing day
Motor skill (both fine and gross) will be assessed and quantified via standard UHDRS motor exam and Q-Motor/Q-Cog equipment suite.
Time frame: 10 minutes for blood draw out of 7-8 hour testing day
Plasma samples will be sent for each visit to University College of London for analysis of NfL, an indicator of neuronal damage determine viability as a biomarker for Huntington's Disease.
Time frame: 10 minutes for vitals collection out of 7-8 hour testing day
Analyses will control for age, sex and height/weight. Age will be recorded in whole months. Sex will be recorded as gender assigned at birth with current gender identity noted. Height will be measured in centimeters, and weight will be measured in kilograms.
University of Iowa
Other
Longitudinal Assessment of Brain Structure and Function in Juvenile Onset Huntington's Disease (JoHD)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07213648
Anxiety Disorders, Basal Ganglia Diseases
Charlottesville, Virginia, United States
View Trial DetailsNCT02994719
Ataxia, Ataxia, Spinocerebellar
Boston, Massachusetts, United States
View Trial DetailsNCT05596760
Alzheimer Disease, Arterial Occlusive Diseases
Seattle, Washington, United States
View Trial DetailsNCT05686551
Basal Ganglia Diseases, Brain Diseases
Birmingham, Alabama, United States
View Trial Details